BioPharma Resources

Drug Trial Radar · NCT06709014

A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD

A 6-month & 18-month Prospective, Randomized, Placebo-controlled, Double-blind Dual Clinical Trial Investigating Efficacy and Safety of Buntanetap in Treating Participants of Early Alzheimer's Disease

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 861 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

861

Actual

Start

Feb 4, 2025

Primary completion

Dec 2027

Study completion Jun 2028

Sponsor

Lead sponsor
Annovis Bio Inc.Industry
Sponsor type
Industry
Collaborators
Prevail Infoworks; ProPharma Group
First posted
Nov 29, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 55 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if buntanetap/Posiphen works to treat early Alzheimer's disease in adults aged 55-85. It will also learn about the safety of buntanetap/Posiphen. The main questions it aims to answer are: * Does buntanetap/Posiphen improve cognition as measured by ADAS-Cog13? * Does buntanetap/Posiphen improve function as measured by ADCS-iADL? * What medical issues do participants have, if any, when taking buntanetap/Posiphen? Researchers will compare buntanetap/Posiphen to a placebo (a look-alike substance that contains no drug) to see if buntanetap/Posiphen works to treat early Alzheimer's disease. Participants will: * Take buntanetap/Posiphen or a placebo every day for 18 months * Visit the clinic periodically for checkups, tests, and questionnaires (screening visits, enrollment, month 1, month 3, month 6, month 9, month 12, month 15, month 18), including a volumetric MRI at month 6 and month 18 * Complete pre- and post-clinic visit phone calls

Conditions

  • Early Alzheimers Disease

Interventions

  • buntanetap/posiphenDrug

    30mg capsule by mouth once daily for 18 months

  • PlaceboDrug

    Placebo capsule by mouth once daily for 18 months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Alzheimer's Disease Assessment Scale-Cognitive Subscale 13 (ADAS-Cog13)Time frame: From screening to 6-month readout, to end of treatment at 18 months.
  2. Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living Scale (ADCS-iADL)Time frame: From screening to 6-month readout, to end of treatment at 18 months.

Locations

78 sites in 1 country. Site status is shown where the registry gives one.

  • MD First Research

    Chandler, Arizona

  • Xenoscience

    Phoenix, Arizona

  • Clinical Endpoints

    Scottsdale, Arizona

  • Advanced Research Center

    Anaheim, California

  • Hope Clinical Research

    Canoga Park, California

  • Sun Valley Research

    Imperial, California

  • Mary S. Easton Center for Alzheimer's Research and Care, UCLA

    Los Angeles, California

  • UC Davis Alzheimer's Disease Research Center

    Sacramento, California

  • The Neuron Clinic

    San Marcos, California

  • Mountain Neurological Center

    Basalt, Colorado

  • CenExel Rocky Mountain

    Englewood, Colorado

  • Research Center for Clinical Trials

    Norwalk, Connecticut

  • Visionary Investigators Network

    Aventura, Florida

  • SFM Clinical Research

    Boca Raton, Florida

  • K2 Medical Research

    Clermont, Florida

  • K2 Medical Research Daytona

    Daytona Beach, Florida

  • Neuropsychiatric Research Center

    Fort Myers, Florida

  • Velocity Clinical

    Hallandale, Florida

  • Jacksonville Center for Clinical Research

    Jacksonville, Florida

  • K2 Medical Research

    Lady Lake, Florida

  • Headlands Research JEM

    Lake Worth, Florida

  • Accel Research Sites Lakeland (Alcanza)

    Lakeland, Florida

  • K2 Medical Research

    Maitland, Florida

  • ClinCloud Clinical Research

    Melbourne, Florida

  • Flourish Research/Merritt Island Medical Research

    Merritt Island, Florida

  • Miami Jewish Health

    Miami, Florida

  • Aqualane Clinical Research

    Naples, Florida

  • Suncoast Clinical Research

    New Port Richey, Florida

  • Conquest Research

    Orlando, Florida

  • Axiom Brain Health, LLC

    Tampa, Florida

  • Conquest Research

    Winter Park, Florida

  • Accel Neurosciences

    Decatur, Georgia

  • CARE (Center for Advanced Research & Education)

    Gainesville, Georgia

  • Hawaii Pacific Neuroscience

    Honolulu, Hawaii

  • Re:Cognition Chicago

    Chicago, Illinois

  • Rush University Medical Center

    Chicago, Illinois

  • Charter Research Chicago

    Chicago, Illinois

  • Great Lakes Clinical Trials/Flourish Research

    Chicago, Illinois

  • Southern Illinois University

    Springfield, Illinois

  • JWM Research

    Indianaopolis, Indiana

Showing 40 of 78 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.